How a natural vitamin D–like molecule (20(OH)D3) helps skin health
Mechanism of action and function of novel secosteroid 20(OH)D3 in the skin
Researchers are testing whether a naturally made vitamin D-like molecule called 20(OH)D3 can protect skin, reduce inflammation, and slow abnormal skin cell growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11269224 on NIH RePORTER |
What this research studies
This research follows a vitamin D-related molecule called 20(OH)D3 that is found in human skin and blood. Scientists study its effects on skin cells, animal models, and human skin samples to see how it influences the skin barrier, inflammation, repair, and cancer-related cell behavior. They are mapping which receptors the molecule acts on (for example VDR, AhR, LXR, and ROR) and looking for metabolite forms that work without raising blood calcium. The team also examines safety at doses that might be used as topical or systemic therapies.
Who could benefit from this research
Good fit: People with inflammatory skin conditions (such as psoriasis or eczema), those with damaged or radiation-exposed skin, or individuals at higher risk of skin cancer who can provide skin samples or join future clinical tests would be most likely to participate.
Not a fit: People without skin-related problems or those needing immediate, proven treatments should not expect direct benefit from this preclinical and mechanistic research at this time.
Why it matters
Potential benefit: If successful, this work could lead to new, safe skin treatments for inflammation, wound healing, radioprotection, and possibly prevention or treatment of some skin cancers.
How similar studies have performed: Early laboratory and animal work by this and other teams shows promising anti-inflammatory and anti-cancer effects, but well-controlled human clinical trials are still lacking.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Slominski, Andrzej T — University of Alabama at Birmingham
- Study coordinator: Slominski, Andrzej T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.